Hosted on MSN17h
Akero’s cirrhosis treatment shows promise in Phase IIb studyIn subjects with baseline and week 96 biopsies, 39% of those treated with a 50mg dosage experienced cirrhosis reversal.
Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...
The scarring that occurs with cirrhosis is usually irreversible, but treatment can help manage it. Causes of cirrhosis include metabolic dysfunction-associated steatotic liver disease (MASLD ...
News Medical on MSN1d
Study explores whether dietary supplement could provide first effective treatment for cirrhosisThe BOOST trial - led by researchers at the University of Plymouth and experts across the UK - will assess whether the Β-hydroxy β-methylbutyrate (HMB) supplement can benefit some of the 60,000 people ...
Akero Therapeutics’ impressive performance in both stock price and clinical trials has made it a stock to watch in 2025. With a promising treatment on the horizon and significant gains to show for it, ...
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...
A Cleveland Clinic study reveals that bariatric surgery significantly reduces the risk of serious liver complications in ...
Akero Therapeutics (AKRO) released preliminary topline week 96 results from SYMMETRY, a Phase 2b study evaluating the efficacy and safety of ...
News Medical on MSN2d
Weight-Loss Surgery Reduces Liver Disease Complications in Obese Patients With CirrhosisA new study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric surgery significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results